Singh Biotechnology

Singh Biotechnology, founded in 2008 and based in San Diego, is a private biotechnology company developing therapeutics using its disruptive single-domain antibody (sdAb) platform. This technology enables the creation of small, stable antibodies that can cross cell membranes and the blood-brain barrier to target intracellular disease drivers like STAT3, KRAS, and TNF-alpha. The company is pre-revenue and in the pre-clinical/early clinical stage, with its most advanced program, SBT-100, holding orphan drug designations for two cancer indications. Its business model is centered on advancing its proprietary pipeline toward clinical validation and potential partnerships.

Proprietary single-domain antibody (sdAb) platform engineering miniature antibodies (VHH) that can cross cell membranes and the blood-brain barrier to target intracellular proteins.

The company competes in the targeted protein degradation and intracellular inhibition space against firms developing small molecules, peptides, and other biologic modalities. For STAT3 inhibition, it faces competition from both direct inhibitors and upstream pathway blockers. Its sdAb approach must differentiate itself on efficacy, safety, and delivery compared to these established and emerging technologies.